Baxter tops Q3 estimates, FY20 guidance raise below consensus

• Baxter International (BAX) Q3 results:
• Revenues: $2,972M (+4.2%).
• Sales by GBU: Renal Care: $955M (+4%); Medication Delivery: $680M (-3%); Pharmaceuticals: $540M (+2%); Clinical Nutrition: $237M (+8%); Advanced Surgery: $236M (+9%); Acute Therapies: $177M (+36%); Other: $147M (+5%).
• Net Income: $356M (-3.5%); EPS: $0.69 (-2.8%); non-GAAP Net Income: $431M (+11.7%); non-GAAP EPS: $0.83 (+12.2%).
• CF Ops: $1,158M (-9.6%).
• 2020 Guidance: GAAP sales growth: up low single digit from (1%) - 1%; GAAP EPS: $2.41 - 2.44 from $2.40 - $2.50; non-GAAP EPS: $3.02 - 3.05 from $3.00 - 3.10 (consensus $3.06).
• https://seekingalpha.com/news/3628165-baxter-tops-q3-estimates-fy20-guidance-raise-below-consensus